The B2B platform for the best purchasing descision. Identify and compare relevant B2B manufacturers, suppliers and retailers
Filter
Locations
Result types
Type of company
Select company type
Industries
Select industry
Company status
Select company status preset
Number of employees
Min.
Max.
Founding year
Lock keywords
Exclude keywords
Optional keywords
Redcar, United Kingdom
In the world of injectable therapeutics, your process is your product. At Micropore we partner for the life of your product, working together to solve formulation challenges and deliver the highest performing, most sustainable, most cost-effective drug product manufactuing systems.
+
Featured
CEPI partners with RVAC Medicines and Micropore Technologies to advance next-generation mRNA vaccine manufacturing platform
... CEPI partners with RVAC Medicines and Micropore Technologies to advance next-generation mRNA vaccine manufacturing ...
Vienna, Austria
1-10 Employees
2016
Nuvonis is a biotech company based in Vienna, Austria, providing innovative cell banks and technical support for vaccine development. The Nuvonis team is highly experienced in all aspects of vaccine production, both in small biotech companies up to major international pharmaceutical companies. Based on our experience, Nuvonis offers solutions that reduce development timelines, ensure optimal quality and prevent risks in your product development. The fully characterised Nuvonis Vero cells (GMP) are cultivated without animal-derived media or protease additives and are non-tumorigenic beyond the end of production passage. We are offering proprietary and efficient virus purification processes for the generation of high-purity vaccine bulk drug substance with low host cell DNA and protein impurities. Nuvonis has developed a novel continuous avian cell line (CCX) from primary quail (Coturnix japonica). Nuvonis avian cell banks are available both for adherent growth and growth in suspension. Nuvonis provides “ready to use” GMP Master and GMP Working Cell Banks.
+
Featured
Technology | Nuvonis
... „Ready to Use“ R&D and GMP Cell Banks for Vaccine Manufacturing ...
Ottawa, Canada
11-50 Employees
2018
We pioneered a new product category of Viral Sensitizers (VSE™) that removes the barriers to manufacturing effective viral medicines at scale. Customized VSE formulations optimize research processes and enhance production. Virica was founded in 2018 based on a decade of research in the laboratory of Dr. Recent influenza outbreaks and the COVID-19 pandemic highlight the need for scalability in the production of vaccines. Virica has the products and experience to combat these challenges. Here is a snapshot of organizations with whom we share knowledge by attending meetings or giving presentations. Virica is a member of BIOTECanada, an association building a climate for biotechnology firms to succeed in today’s hyper-competitive economy. Virica is a member of Alliance of Regenerative Medicine.
+
Featured
Virica Biotech - Viral Sensitizers (VSE)
... Government of Ontario Invests in Virica Biotech to Expand Domestic Vaccine Manufacturing ...
Diegem, Belgium
1001-5000 Employees
1973
We manage the design, construction and commissioning of high-tech facilities. Over 50+ years, we’ve built our expertise working for the world's leading pharma, food, data centre and medical technology companies. People are at the centre of our 2025 strategy, “Delivering our Future Together”. They are the foundation of our success and bring our vision, mission and values to life every day. Our approach has led to long-term, trusted relationships with our clients. We hire talented people who are passionate about project delivery. Established in 1973, our story began in a small office in Dublin, Ireland. During the past decades, we have built our company around excellent service and great people.
+
Featured
Sterile filling & freeze-drying vaccine manufacturing project Netherlands
... Sterile filling & freeze-drying vaccine manufacturing project ...
Makkajipalli, India
11-50 Employees
2019
We provide services to develop and manufacture high-quality Vaccines and Biologics/Bio-therapeutic, to support global biotechnology and biopharma companies, meeting customer satisfaction in compliance with Quality, Regulatory and GMP expectations. Yapan Bio is a Contract Development and Manufacturing Organization (CDMO) serving the needs of the biotechnology industry, globally. Yapan Bio provides robust process development, appropriate scale-up and compliant GMP manufacturing of Vaccines and Biologics/Bio-therapeutics for human clinical studies across the world. Yapan Bio has established state-of-the-art Process Development and GMP facilities for vaccines and biologics, including higher Bio-Safety levels (up to BSL-2+). To provide customized high-quality integrated services to our partners. Yapan Bio was founded by two industry veterans, Atin Tomar and Nirav Desai, with a proven leadership track record in both technical and leadership roles in the biotechnology industry, globally. Yapan Bio’s focus and expertise is in the development and manufacturing of next generation and highly complex molecules/products (recombinant vaccines, viral and non-viral vector-based products, Gene Therapy, monoclonal antibodies etc.). Optimization and scale-up for high product titer, stability and consistent manufacturing output.
+
Featured
HOME | Yapan Bio
... Your Collaborative Partner in Process Development and GMP Manufacturing of Vaccines and Biologics/Bio-therapeutics. ...
Morrisville, United States
1001-5000 Employees
2011
We are actively involved with many of the major industry organizations and professional associations. FUJIFILM Diosynth Biotechnologies is a CDMO partner for life. FUJIFILM Diosynth Biotechnologies is a leading contract development and manufacturing organization (CDMO) providing the development and manufacturing of biologics, vaccines and advanced therapies with a global network in the following locations:. FUJIFILM Diosynth Biotechnologies is proud of its history of strong and productive partnerships. We offer a work environment that promotes individual responsibility and growth, a collaborative spirit, and an atmosphere that encourages learning and professional development. We aim to be the leading and most trusted Partner for Life in the biopharmaceutical industry, transforming the customer experience using trust as the cornerstone. To be the leading and most trusted global Contract Development and Manufacturing Organization in the biopharmaceutical industry. As proud members of the FUJIFILM family with a world-wide presence, we are one of the leading and most trusted global contract development and manufacturing organizations in the biopharmaceutical industry.
+
Featured
“Ready To Save The World” With Mass Vaccine Manufacturing
... “READY TO SAVE THE WORLD” WITH MASS VACCINE MANUFACTURING | FUJIFILM Diosynth ...
Swedesboro, United States
51-100 Employees
1900
We're sorry, due to the EU GDPR requirements we are unable to service content at this time.
+
Featured
Thomas Scientific - Lab Supplies, Lab Equipment, Lab Chemicals, & Lab Safety
... Protecting people, products, and processes during vaccine manufacturing ...
Singapore
11-50 Employees
2022
Our mission is to provide BIM services of the highest quality and help our Clients to design, construct and operate better. Design better, construct safer, operate easier by using full leverage of BIM Technology. Our Core Value is to satisfy Clients and deliver product using innovative technology with superior quality, value, and service:. The Singapore Refinery is a world-scale refining complex across two sites - one on the mainland and another on Jurong Island. First-in-Asia, fully digitalised vaccine manufacturing facility in Singapore. Know more about innovative technology and how you can get benefits after implementation them. Find how new technologies may assist to deliver project in time and safe your budget.
+
Featured
Home - BIM SECTOR
... BIM is that it’s moving us back to Interdisciplinary work” – Kathleen Liston ongoing projects Vaccine Facility First-in-Asia, fully digitalised vaccine manufacturing facility in Singapore Learn More Data Center The biggest Data Center project in Asia Learn More Explore The … Home Read More » ...
+
Featured
COVID-19 Vaccine Manufacturing Efforts
... COVID-19 Vaccine Manufacturing ...
Upper Merion Township, United States
51-100 Employees
1962
We are pleased to have the opportunity to contribute to the battle against COVID-19 while continuing to help our clients with their “normal” activities. Many of our existing offerings that we have helped clients with over the years are particularly important at this time; e.g. Tunnell Government Services is supporting a variety of agencies as the government focuses on rapid vaccine, therapeutic and diagnostic development. Tunnell helps you navigate the regulatory landscape throughout the product life cycle.
+
Featured
Home - Tunnell Consulting
... Assessing Risk in Seeds & Cell Banks Practices: Avoid Costly Disruptions in Vaccine Manufacturing ...
Technologies which have been searched by others and may be interesting for you:
Some interesting numbers and facts about the results you have just received for Vaccine Manufacturing
| Country with most fitting companies | United States |
| Amount of fitting manufacturers | 27 |
| Amount of suitable service providers | 23 |
| Average amount of employees | 51-100 |
| Oldest suiting company | 1900 |
| Youngest suiting company | 2022 |
Vaccine manufacturing is a complex, multi-stage process that involves the production of vaccines to ensure immunity against various infectious diseases. It starts with the exploration and identification of antigens that can trigger an immune response. Following this, the development phase includes small-scale experiments to determine the method of vaccine creation, whether it be through attenuated or inactivated pathogens, recombinant technology, or mRNA techniques. Once a viable method is established, the process moves to large-scale production, where the vaccine is produced in significant quantities under stringent quality control measures to ensure its safety and efficacy. The final steps involve rigorous testing, packaging, and distribution. The role of vaccine manufacturing within the medical field is pivotal; it not only enables the mass production of vaccines, crucial for public health initiatives and preventing outbreaks of infectious diseases but also fosters innovation in vaccine technology and production methods. This sector's advancements directly impact global health by enabling more efficient responses to emerging infectious diseases, enhancing the effectiveness of vaccines, and making them accessible to broader populations worldwide. Through its contributions, vaccine manufacturing plays a critical role in disease prevention, health promotion, and the overall betterment of public health outcomes, marking its significance in the medical and pharmaceutical industries.
1. Enhanced Quality Control
Vaccine manufacturing enables strict oversight over the production process, ensuring high-quality outcomes. Unlike other methods, this controlled environment minimizes the risk of contamination, leading to safer vaccines for public use.
2. Scalability
The ability to scale production up or down based on demand is a significant advantage of vaccine manufacturing. This flexibility ensures that during health crises, manufacturers can quickly increase production to meet the urgent needs of the global population.
3. Cost-Effectiveness
Over time, the investment in vaccine manufacturing facilities pays off as the per-unit cost of vaccines decreases with larger production volumes. This cost reduction makes vaccines more accessible to a wider audience, contributing to global health initiatives.
4. Innovation and Adaptation
Vaccine manufacturing fosters innovation, allowing scientists and researchers to quickly adapt to new challenges, such as emerging infectious diseases. This agility is crucial in developing vaccines against novel pathogens in a timely manner.
While evaluating the different suppliers make sure to check the following criteria:
1. Regulatory Compliance
Ensure the supplier adheres to international and local regulatory standards, such as the FDA or EMA, for vaccine manufacturing. This is crucial for the safety and efficacy of the vaccines produced.
2. Quality Assurance Systems
Examine the supplier's quality assurance systems and their track record for consistency in vaccine production. This includes Good Manufacturing Practices (GMP) certification, which is essential for maintaining high-quality standards.
3. Capacity and Scalability
Assess the supplier's production capacity and their ability to scale operations to meet demand fluctuations. This is particularly important for responding to health emergencies or scaling up for global distribution.
4. Technological Expertise
Consider the supplier's expertise in the latest vaccine technologies, such as mRNA or viral vector vaccines. This can be indicative of their ability to innovate and produce vaccines that meet current health challenges.
5. Supply Chain Reliability
Evaluate the robustness of the supplier's supply chain, including raw materials sourcing and logistics. A reliable supply chain is critical for ensuring vaccine availability and timely distribution.
In the pharmaceutical industry, vaccine manufacturing plays a critical role in disease prevention and control. Companies specializing in this sector often collaborate with biotech firms for research and development. This partnership accelerates the creation of vaccines by combining biotech innovations with the manufacturing capabilities of pharmaceutical giants, ensuring a swift response to emerging health threats. The healthcare sector also benefits significantly from vaccine production. Hospitals and clinics partner with manufacturers to secure a steady supply of vaccines, safeguarding public health. This collaboration is vital for managing and preventing outbreaks, ensuring that healthcare providers have the necessary resources to protect their communities. Furthermore, governments and public health organizations engage in direct partnerships with vaccine manufacturers. These collaborations are crucial for national vaccination campaigns and emergency response efforts. By securing contracts for vaccine supply, public health authorities can implement widespread immunization programs, aiming to achieve herd immunity against contagious diseases. Lastly, the veterinary and livestock industries rely on vaccine manufacturing to prevent animal diseases. By collaborating with manufacturers, these sectors ensure the health and well-being of livestock, which is essential for food security and agricultural productivity. This partnership not only protects animal health but also supports the global food supply chain.
Vaccine manufacturing currently operates at a high Technology Readiness Level (TRL), often considered to be between TRL 8 and TRL 9, indicative of technologies that have been fully developed, tested, and validated in real-world conditions. This advanced TRL reflects significant technological advancements in recent decades, including the development of recombinant DNA technology, mRNA synthesis, and viral vector platforms, which have drastically improved the speed, efficiency, and safety of vaccine production. The COVID-19 pandemic underscored the effectiveness of these technologies, as mRNA vaccines were developed, tested, and deployed at an unprecedented scale and speed, showcasing a level of maturity and readiness for immediate application to meet global health needs. Additionally, continuous improvements in bioreactor designs, purification processes, and quality control measures have further bolstered the robustness and scalability of vaccine manufacturing. These technical achievements underscore the industry's ability to respond rapidly to emerging infectious diseases, highlighting the high TRL of vaccine manufacturing as a testament to the cumulative knowledge, experience, and technological innovations honed over years of research and public health challenges.
In the Short-Term, the landscape of vaccine manufacturing is set to witness significant advancements in mRNA technology, streamlining the development and production process. This method, heralded for its pivotal role in COVID-19 vaccine creation, is expected to become more efficient and cost-effective, enabling rapid response to emerging infectious diseases. The integration of artificial intelligence for predictive analysis and optimization of vaccine formulations will also play a crucial role, enhancing the precision and effectiveness of vaccines. Moving into the Mid-Term, the focus will shift towards scalable and flexible manufacturing systems. These systems, leveraging modular and portable production units, will facilitate localized vaccine production, reducing logistical challenges and improving access in remote areas. The advent of viral vector vaccines will see further refinement, offering robust platforms for a wide range of infectious diseases. Additionally, the use of nanoparticle technology is anticipated to improve vaccine stability and storage, eliminating the need for ultra-cold chain logistics. In the Long-Term, the frontier of vaccine manufacturing will explore the realms of personalized vaccines and next-generation adjuvants. Cutting-edge research into individual genetic and immunological profiles will pave the way for highly personalized vaccine therapies, targeting cancers and chronic diseases with unprecedented precision. Moreover, the development of novel adjuvants will enhance the efficacy and longevity of immune responses, marking a new era in vaccine technology where prevention can be as tailored and specific as the treatment of diseases.
